Nimotuzumab binds to the extracellular domain of epidermal growth factor receptor (EGFR, HER1, c-ErB1) and inhibits the binding of epidermal growth factor (EGF) and other ligands such as transforming growth factor alfa. Binding of nimotuzumab to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased vascular endothelial growth factor production.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| BIOMAB EGFR Solution for infusion | MPI, US: SPL/Old |
Nimotuzumab is an active ingredient of these brands:
Brazil (BR)Ecuador (EC)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.